Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 18, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FORBES-TATE
- Client
- AMGEN USA, INC.
- Filing UUID
- 45ee4e38-770a-4112-acea-add937204c20
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.